Apolipoprotein A1: A new serum marker correlated to JAK2 V617F proportion at diagnosis in patients with polycythemia vera

Proteomics - Clinical Applications

Volumn 1, Issue 12, 2007, Pages 1605-1612

  Mossuz, Pascal ^a   Bouamrani, Ali ^b   Brugière, Sabine ^c   Arlotto, Marie ^b   Hermouet, Sylvie ^d   Lippert, Eric ^e   Laporte, François ^a   Girodon, François ^f   Dobo, Irène ^g   Vincent, Praloran ^e   Garin, Jérome ^c   Cahn, Jean Yves ^c   Berger, François ^b  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

^c UNIV GRENOBLE ALPES   (France)

^d NANTES UNIVERSITY HOSPITAL   (France)

^e BORDEAUX UNIVERSITY HOSPITAL   (France)

^f DIJON UNIVERSITY HOSPITAL   (France)

^g ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

Apolipoprotein A1; Biomarker; Polycythemia vera; Surface enhanced laser desorption ionization time of flight mass spectrometry (SELDI TOF MS)

Indexed keywords

APOLIPOPROTEIN A1; BIOLOGICAL MARKER; JANUS KINASE 2; PLASMA PROTEIN;

ALLELE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; DIAGNOSTIC VALUE; GENE MUTATION; HEMATOLOGICAL PARAMETERS; HUMAN; IMMUNOASSAY; MYELOPROLIFERATIVE DISORDER; PATIENT CODING; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

EID: 38349184551     PISSN: 18628346     EISSN: None     Source Type: Journal    
DOI: 10.1002/prca.200601051     Document Type: Article

References (26)

1. James, C., Ugo, V., Casadevall, N., Staerk, J. et al., A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera. Nature 2005, 434, 1144-1148.
2. Levine, R. L., Wadleigh, M., Cools, J., Ebert, B. L. et al., Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7, 387-397.
3. Baxter, E. J., Scott, L. M., Campbell, P. J., East, C. et al., Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365, 1054-1061.
4. Kralovics, R., Passamonti, F., Buser, A. S., Teo, S. S. et al., A gain of function mutation of JAK2 in myeloproliferative disorders. New Engl. J. Med. 2005, 352, 1779-1790.
5. Zhao, R., Xing, S., Li, Z., Fu, X. et al., Identification of an acquired JAK2 mutation in Polycythemia Vera. J. Biol. Chem. 2005, 280, 22788-22792.
6. Lacout, C., Pisani, D. F., Tulliez, M., Moreau Gachelin, F. et al., JAK2 V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 2006, 108, 1652-1660.
7. James, C., Ugo, V., Casadevall, N., Staerk, J. et al., A JAK2 mutation in myeloproliferative disorders: Pathogenesis and scientific prospects. Trends Mol. Med. 2005, 11, 545-554.
8. Passamonti, F., Rumi, E., Pietra, D., Della Porta, M. G. et al., Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood 2006, 107, 3676-3682.
9. Spivak, J. L., Moliterno, A. R., Williams, D. M., Jie, C., Genotype and phenotype in the chronic myeloproliferative disorders, European School of Haematology, Madeira, Portugal, September 2006.
10. V617F in Polycythemia Vera. Cancer 2006, 106, 631-635.
11. Lippert, E., Boissinot, M., Kralovics, R., Gordon, F. et al., The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood 2006, 108, 1865-1867.
12. Kralovics, R., Teo, S. S., Buser, A., Brustsche, M. et al., Altered gene expression in myeloproliferative disorders correlates with activation of signalling by the V617F mutation of Jak2. Blood 2005, 106, 3374-3376.
13. V617F mutational load at diagnosis on major clinical aspects in patients with Polycythemia Vera. Blood (ASH annual meeting abstracts) 2006, 108, abstract 5.
14. Mossuz, P., Girodon, F., Donnard, M., Latger-Cannard, V. et al., Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis. Haematologica 2004, 89, 1194-1198.
15. Panteli, K. E., Hatzimichael, E. C., Bouranta, P. K., Katsaraki, A. et al., Serum interleukin (IL)-1, IL2, sIL-2Ra, IL6 and thrombopoietin levels in patients with chronic myeloproliferative diseases. Br. J. Haematol. 2005, 130, 709-715.
16. Paradis, V., Degos, F., Dargere, D., Pham, N. et al., Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases. Hepatology 2005, 41, 40-47.
17. Zhang, Z., Bast, R. C., Yu, Y., Li, J. et al., Three biomarkers identified from serum proteomic analysis for the detection of early stage of ovarian cancer. Cancer Res. 2004, 64, 5882-5890.
18. Hegedus, C. M., Gunn, L., Skibola, C. F., Zhang, L. et al., Proteomic analysis of childhood leukaemia. Leukemia 2005, 19, 1713-1718.
19. Albitar, M., Potts, S. J., Giles, F., O'Brien, S. et al., Proteomic-based prediction of clinical behaviour in adult acute lymphoblastic leukaemia. Cancer 2006, 106, 1587-1594.
20. Klippel, S., Strunck, E., Temerinac, S., Bench, A. J. et al., Quantification of PRV-1 mRNA distinguished polycythemia vera from secondary erythrocytosis. Blood 2003, 102, 3569-3574.
21. Aspinall, J. O., Bentel, J. M., Horsfall, D. J., Haagensen, D. E. et al., Differential expression of Apolipoprotein-D and prostate specific antigen in benign and malignant prostate tissues. J. Urol. 1995, 154, 622-628.
22. Hall, R. E., Horsfall, D. J., Stahl, J., Vivekanandan, S. et al., Apolipoprotein-D: A novel marker for HGPIN and prostate cancer. Prostate 2004, 58, 103-108.
23. Tachibana, M., Ohkura, Y., Kobayashi, Y., Sakamoto, H. et al., Expression of Apolipoprotein-A1 in colonic adenocarcinoma. Anticancer Res. 2003, 23, 4161-4167.
24. Malik, G., Ward, M. D., Gupta, S. K., Trosset, M. W. et al., Serum levels of an isoform of Apolipoprotein-AII as a potential marker for prostate cancer. Clin. Cancer Res. 2005, 11, 1073-1084.
25. Freeman, V. L., Meydani, M., Hur, K., Flanigan, R. C., Inverse association between prostatic polyinsatured fatty acid and risk of locally advanced prostate carcinoma. Cancer 2004, 101, 2744-2754.
26. Freeman, M. R. Solomon, K. R., Cholesterol and prostate cancer. J. Cell. Biochem. 2004, 91, 54-69.